Levosimendan Altan (Levosimendan)

Levosimendan sensitises cardiac troponin C to calcium, enhancing myocardial contraction without raising intracellular calcium. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, causing vasodilation and lowering after‑load, which together improve cardiac output.

The dosing regimen for levosimendan is determined by the prescribing clinician based on the patient’s clinical condition, weight, and response. Specific dose and infusion rates are individualized and should follow the prescriber’s instructions.

The safety of levosimendan during pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and import documentation.

Unlike traditional catecholamine inotropes, levosimendan increases contractility without raising intracellular calcium, reducing the risk of calcium‑mediated toxicity. Its vasodilatory effect also lowers after‑load, offering a dual mechanism that can be advantageous over agents that act solely on adrenergic pathways.

Levosimendan should be stored at 2‑8 °C, protected from light, and kept in its original packaging. Do not freeze or shake the solution. Once prepared for infusion, it should be used promptly according to aseptic technique.

Levosimendan is given intravenously, typically as an initial loading infusion followed by a continuous maintenance infusion. Administration is performed by qualified healthcare personnel in a monitored clinical setting, with vital signs observed throughout the infusion.

The most serious risks include severe hypotension, ventricular arrhythmias, and rare allergic reactions such as anaphylaxis. Patients should be closely monitored for blood pressure changes and cardiac rhythm disturbances during and after infusion.

Levosimendan is contraindicated in patients with severe hypotension, critical aortic stenosis, or known hypersensitivity to the drug. Caution is also advised for individuals with significant renal or hepatic impairment, and those receiving other potent vasodilators.